| Dec'19 | Sep'19 | Jun'19 | Mar'19 | Dec'18 | Sep'18 | Jun'18 |
|---|---|---|---|---|---|---|
Cash flows from operating activities: | ||||||
Net loss | ||||||
-41,259 | -25,741 | -28,485 | -28,968 | -26,441 | -24,642 | -31,295 |
Adjustments to reconcile net loss to net cash used in operating activities: | ||||||
Depreciation and amortization | ||||||
65 | 59 | 54 | 48 | 47 | 45 | 40 |
Share-based compensation expense | ||||||
12,529 | 1,221 | 1,047 | 1,350 | 833 | 989 | 806 |
Amortization of debt discount and issuance costs | ||||||
312 | 158 | 194 | - | - | - | - |
Amortization of operating lease right-of-use assets | ||||||
- | - | 63 | - | - | - | - |
Loss on disposal of furniture and equipment | ||||||
0 | 0 | -236 | - | - | - | - |
Unrealized foreign currency translation adjustment | ||||||
-29 | 92 | -188 | 51 | -216 | -317 | 220 |
Changes in operating assets and liabilities: | ||||||
Prepaid expenses and other current assets | ||||||
1,194 | 407 | -4,498 | -2,482 | 3,383 | 5,869 | 692 |
Other assets | ||||||
-5 | -5 | -67 | - | - | - | - |
Due to Roivant Sciences Ltd. | ||||||
- | - | 19 | - | - | - | 1,194 |
Accounts payable | ||||||
821 | -1,192 | 834 | -1,771 | -938 | -408 | 4,209 |
Accrued expenses | ||||||
4,898 | 1,320 | -1,220 | 2,869 | -3,032 | 605 | 5,197 |
Net cash used in operating activities | ||||||
-23,563 | -24,463 | -22,505 | -23,971 | -40,721 | -23,583 | -20,761 |
Cash flows from investing activities: | ||||||
Purchases of furniture and equipment | ||||||
143 | 311 | 278 | 400 | 31 | 47 | 115 |
Net cash used in investing activities | ||||||
-143 | -311 | -278 | -400 | -31 | -47 | -115 |
Cash flows from financing activities: | ||||||
Proceeds from capital contributions from Roivant Sciences Ltd. | ||||||
61 | 60 | 130 | 41 | 1,346 | 21,744 | 18,500 |
Proceeds from exercise of stock options | ||||||
498 | 150 | 70 | - | - | - | - |
Debt financing costs paid | ||||||
0 | 0 | 387 | - | - | - | - |
Initial public offering costs paid | ||||||
- | - | - | - | - | 708 | 565 |
Net cash provided by financing activities | ||||||
87,831 | 30,210 | -187 | 14,110 | 135,550 | 21,036 | 17,935 |
Net change in cash, cash equivalents and restricted cash | ||||||
64,125 | 5,436 | -22,970 | -10,261 | 94,798 | -2,594 | -2,941 |
Non-cash financing activities: | ||||||
Furniture and equipment included in accounts payable and accrued expenses | ||||||
- | - | 229 | - | - | - | - |
Furniture and equipment included in due to Roivant Sciences Ltd. | ||||||
- | 0 | 63 | - | - | - | - |
Unpaid initial public offering costs included in accounts payable | ||||||
- | - | - | - | - | 640 | 288 |
Supplemental disclosure of cash paid: | ||||||
Interest | ||||||
774 | 482 | 385 | - | - | - | - |